Cephalon, Inc.

Cephalon, Inc. (NASDAQ:CEPH) and Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced positive interim results from Mesoblast's ongoing multi-center Phase 2 trial of its "off-the-shelf" proprietary adult stem cell product Revascor (TM) for patients with congestive heart failure.

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it had completed its acquisition of United States company Angioblast Systems Inc with the issue of 90.8 million ordinary shares to former Angioblast security holders, increasing the total number of shares on offer to 253.8 million shares. Notably, no former Angioblast security holders elected to take a cash entitlement, resulting in a total saving to Mesoblast of approximately A$47 million.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) and global biopharmaceutical company, Cephalon, Inc. (NASDAQ:CEPH), today announced they have entered into a strategic alliance to develop and commercialize novel adult stem cell therapeutics for degenerative conditions of the central nervous and cardiovascular systems. These conditions include Parkinson's disease, Alzheimer's Disease, Congestive Heart Failure and Acute Myocardial Infarction. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.